Want to see PCSA full AI Analyst Report?
Top Page
Processa Pharmaceuticals
(NASDAQ:PCSA)
Select Model
Select Model
Rating:48Neutral
Price Target:
$3.00
▲(15.38% Upside)
Action:Reiterated
Date:07/30/26
The score is held down primarily by weak financial performance typical of a pre-revenue biotech—persistent losses, substantial cash burn, and a materially reduced equity cushion despite no reported debt. Technicals are a modest offset as the stock is trading above its 20/50/100-day averages, but remaining below the 200-day average keeps the longer-term trend mixed. Valuation support is limited because the negative P/E reflects ongoing losses and no dividend yield is provided.
Positive Factors
Low leverage
Zero reported debt materially reduces near- and medium-term refinancing and interest-rate risk for a cash-burning biotech. That structural low-leverage profile gives management flexibility to prioritize R&D and allocate new capital toward clinical milestones without debt-servicing constraints.
Negative Factors
Persistent cash burn and losses
Sustained negative operating and free cash flow at ~-$15M TTM means the business model is not self-funding and remains dependent on external capital. Over the medium term this creates recurring dilution risk and forces management to prioritize financing and milestone timing over longer-term strategic investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Zero reported debt materially reduces near- and medium-term refinancing and interest-rate risk for a cash-burning biotech. That structural low-leverage profile gives management flexibility to prioritize R&D and allocate new capital toward clinical milestones without debt-servicing constraints.
Read all positive factors
Processa Pharmaceuticals (PCSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.95M
Dividend YieldN/A
Average Volume (3M)62.24K
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue GrowthN/A
EPS Growth86.07%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.66
Shares Outstanding2,768,032
10 Day Avg. Volume76,701
30 Day Avg. Volume62,241
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6
Revenue Forecast (FY)$10.01M
Processa Pharmaceuticals Business Overview & Revenue Model
Company Description
Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The co...
How the Company Makes Money
Processa Pharmaceuticals does not have a recurring product-revenue business model because it is a clinical-stage biopharmaceutical company and, to the extent publicly available information indicates, it does not sell approved drugs. As a result, i...
Processa Pharmaceuticals Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
38
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -301.00 | 0.00 | 0.00 | 0.00 | -874.01K | 0.00 |
| EBITDA | -14.11M | -13.56M | -11.85M | -11.12M | -26.64M | -10.78M |
| Net Income | -14.11M | -13.56M | -11.85M | -11.12M | -27.42M | -11.43M |
Balance Sheet | ||||||
| Total Assets | 4.52M | 7.81M | 3.23M | 5.79M | 8.62M | 26.46M |
| Cash, Cash Equivalents and Short-Term Investments | 1.69M | 5.54M | 1.19M | 4.71M | 6.50M | 16.50M |
| Total Debt | 0.00 | 0.00 | 73.51K | 150.55K | 229.45K | 78.46K |
| Total Liabilities | 1.98M | 2.24M | 1.53M | 797.48K | 1.15M | 978.40K |
| Stockholders Equity | 2.54M | 5.58M | 1.70M | 4.99M | 7.47M | 25.49M |
Cash Flow | ||||||
| Free Cash Flow | -12.25M | -11.39M | -11.25M | -8.07M | -9.61M | -8.72M |
| Operating Cash Flow | -12.25M | -11.39M | -11.25M | -8.06M | -9.61M | -8.72M |
| Investing Cash Flow | -1.35M | -850.00K | -3.24K | -2.78K | 0.00 | 0.00 |
| Financing Cash Flow | 12.39M | 16.58M | 7.73M | 6.27M | -388.84K | 9.80M |
Processa Pharmaceuticals Technical Analysis
Negative
2.60
Price Trends
2.28
Negative
2.52
Negative
3.71
Negative
Market Momentum
0.02
Positive
46.64
Neutral
23.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCSA, the sentiment is Negative. The current price of 2.6 is above the 20-day moving average (MA) of 2.28, above the 50-day MA of 2.28, and below the 200-day MA of 3.71, indicating a bearish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 46.64 is Neutral, neither overbought nor oversold. The STOCH value of 23.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PCSA.
Processa Pharmaceuticals Risk Analysis
Processa Pharmaceuticals disclosed 41 risk factors in its most recent earnings report. Processa Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Processa Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $5.95M | -0.20 | -281.30% | ― | ― | 86.07% | |
48 Neutral | $11.31M | -1.11 | -150.61% | ― | ― | 53.06% | |
45 Neutral | $17.48M | -1.08 | -66.69% | ― | -45.52% | -94.82% | |
42 Neutral | $2.17M | >-0.01 | -694.46% | ― | ― | -92.20% | |
41 Neutral | $8.14M | -0.19 | -246.04% | ― | ― | 54.48% | |
39 Underperform | $7.22M | -0.73 | -201.06% | ― | ― | ― |
* Healthcare Sector Average
PCSA
Processa Pharmaceuticals
2.13
-3.65
-63.15%
CANF
Can-Fite BioPharma
3.17
-10.32
-76.50%
SNGX
Soligenix
0.38
-2.73
-87.88%
LPCN
Lipocine
2.11
-1.02
-32.59%
COCP
Cocrystal Pharma
0.94
-1.00
-51.55%
PHGE
BiomX
0.19
-8.02
-97.73%
Processa Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesLegal ProceedingsM&A TransactionsPrivate Placements and Financing
Processa Pharmaceuticals acquires Vidya, raises strategic funding
Positive
Jul 29, 2026
On July 28, 2026, Processa completed the stock‑for‑stock acquisition of Vidya Therapeutics, bringing Vidya’s lead asset VT‑7208, a next‑generation CNS‑penetrant BTK inhibitor for immune‑mediated diseases, ...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Processa Pharmaceuticals Announces Transition of Chief Development Officer
Neutral
Apr 30, 2026
On April 30, 2026, Processa Pharmaceuticals approved a planned transition toward retirement for Dr. Sian Bigora, its Chief Development and Regulatory Officer. Effective May 1, 2026, she moved from a full-time executive officer role to a part-time ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.